Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.
复制标题
DOI：
10.1111/1756-185x.13031
复制
发表时间：
2018-11
影响因子：
2.5
通讯作者：
Gorrell MD
中科院分区：
文献类型：
--
作者：
Sinnathurai P;Lau W;Vieira de Ribeiro AJ;Bachovchin WW;Englert H;Howe G;Spencer D;Manolios N;Gorrell MD
定量类风湿性关节炎（RA）、系统性硬化症（SSc）患者和机械性背痛对照组的循环成纤维细胞活化蛋白（cFAP）和二肽基肽酶4（cDPP 4）蛋白酶活性，并将血浆水平与疾病特征相关联。从RA患者（n=73）、SSc患者（n=37）和对照受试者（n=26）采集血浆。使用特异性酶活性测定来定量DPP4和FAP。与对照组相比，RA组（p=0.02）和SSc组（p=0.002）的中位cDPP4显著较低。三组之间的中位cFAP没有显著差异。DPP4和FAP与炎症标志物和疾病持续时间呈负相关。在类风湿关节炎的疾病亚型，包括血清阳性和糜烂性疾病没有关联。在患有肌炎的SSc患者中发现cDPP 4减少。接受泼尼松（p=0.001）或来氟米特（p=0.04）治疗的RA患者血浆FAP较低，但接受生物制剂治疗的患者血浆FAP较高（p=0.01）。接受来氟米特治疗的RA患者cDPP4也降低（p=0.014）。接受泼尼松（p=0.02）的SSc患者的cDPP 4较低，但与cFAP无关。未发现cFAP与RA或SSc之间存在关联。与对照组相比，RA和SSc的血浆DPP4降低。cDPP4和cFAP与炎症标志物呈负相关，与该RA队列中的疾病特征无显著相关性。
To quantify circulating fibroblast activation protein (cFAP) and dipeptidyl peptidase 4 (cDPP4) protease activities in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and a control group with mechanical back pain and to correlate plasma levels with disease characteristics. Plasma was collected from patients with RA (n=73), SSc (n=37) and control subjects (n=26). DPP4 and FAP were quantified using specific enzyme activity assays. Median cDPP4 was significantly lower in the RA group (p=0.02), and SSc group (p=0.002) compared with controls. There were no significant differences in median cFAP between the three groups. DPP4 and FAP demonstrated a negative correlation with inflammatory markers and duration of disease. There were no associations with disease subtypes in RA, including seropositive and erosive disease. Decreased cDPP4 was found in SSc patients with myositis. Plasma FAP was lower in RA patients receiving prednisone (p=0.001) or leflunomide (p=0.04), but higher with biologic agents (p=0.01). RA patients receiving leflunomide also had decreased cDPP4 (p=0.014). SSc patients receiving prednisone (p=0.02) had lower cDPP4 but there was no association with cFAP. No association was found between cFAP and RA or SSc. Plasma DPP4 was decreased in RA and SSc when compared with controls. cDPP4 and cFAP correlated negatively with inflammatory markers and there were no significant correlations with disease characteristics in this RA cohort.